


# Stabilis



## Mitoxantrone dihydrochloride



Noms commerciaux

Bluxantron	Equateur
Bresnix	Mexique
Ebexantron	Autriche
Elsep	France
Formyxan	Colombie, Equateur, Mexique
Genefadrone	Grèce
Mitoxgen	Argentine
Neotalem	Mexique
Novantron	Allemagne, Autriche, Suisse
Novantrone	Afrique du sud, Belgique, Chili, Danemark, Emirats Arabes Unis, Espagne, Etats Unis d'Amérique, France, Grèce, Hongrie, Irlande, Italie, Luxembourg, Malaisie, Maroc, Norvège, Nouvelle Zélande, Roumanie, Slovénie, Suède, Thaïlande, Turquie
Onkotrone	Allemagne, Australie, Grande Bretagne, Italie, Luxembourg, Roumanie
Ralenova	Allemagne
Refador	Hongrie
Santrone	Egypte, Malaisie
Strimax	Espagne
Xantrosin	Belgique



### Stabilité des solutions

		0,04 >> 0,12 mg/ml	2-8°C		28			2344
		0,04 >> 0,12 mg/ml	20-25°C		7			2344
		0,3 >> 0,5 mg/ml	2-8°C		28			2344
		0,3 >> 0,5 mg/ml	20-25°C		28			2344
		0,04 >> 0,5 mg/ml	2-8°C		7			2344
		0,04 >> 0,5 mg/ml	20-25°C		7			2344
		0,2 mg/ml	37°C		14			484
		0,2 mg/ml	4°C		14			484

		0,04 & 0,4 mg/ml	23°C		7			828
		0,04 & 0,4 mg/ml	4°C		7			828
		0,3 >> 0,5 mg/ml	2-8°C		28			2344
		0,3 >> 0,5 mg/ml	20-25°C		28			2344
		0,04 >> 0,5 mg/ml	2-8°C		7			2344
		0,04 >> 0,5 mg/ml	20-25°C		7			2344
		0,04 >> 0,12 mg/ml	2-8°C		28			2344
		0,04 >> 0,12 mg/ml	20-25°C		7			2344
		0,3 >> 0,5 mg/ml	2-8°C		28			2344
		0,3 >> 0,5 mg/ml	20-25°C		28			2344
		0,04 >> 0,5 mg/ml	2-8°C		7			2344
		0,04 >> 0,5 mg/ml	20-25°C		7			2344
		0,2 mg/ml	20°C		28			1317
		0,2 mg/ml	4°C		28			1317



### Stabilité en mélange

		1 mg/ml	25°C		Etoposide : 10 mg/ml	22		1730
		0,05 mg/ml	25°C		Etoposide : 0,5 mg/ml	22		1730



### Facteur influençant la stabilité

				301
--	--	--	--	-----



### Compatibilités

		Mitoxantrone dihydrochloride : 0,5 mg/ml Amphotericin B cholesteryl sulfate complex : 0,83 mg/ml	921
		Mitoxantrone dihydrochloride : 0,5 mg/ml Aztreonam : 40 mg/ml	99
		Mitoxantrone dihydrochloride : 0,5 mg/ml	301
		Mitoxantrone dihydrochloride : 0,5 mg/ml	1415

		Mitoxantrone dihydrochloride : 0.5 mg/ml Allopurinol sodium : 3 mg/ml		307
		Mitoxantrone dihydrochloride : 0.5 mg/ml Amifostine : 10 mg/ml		3
		Mitoxantrone dihydrochloride : 0.5 mg/ml Cladribine : 0.5 mg/ml		1496
		Mitoxantrone dihydrochloride : 0.5 mg/ml Cladribine : 0.015 mg/ml		1496
		Mitoxantrone dihydrochloride : 0.5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Mitoxantrone dihydrochloride : 0,05 & 1 mg/ml Etoposide : 0,5 & 10 mg/ml		1730
		Mitoxantrone dihydrochloride : 0.5 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Mitoxantrone dihydrochloride : 0.5 mg/ml Filgrastim : 30 µg/ml		244
		Mitoxantrone dihydrochloride : 0.5 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Mitoxantrone dihydrochloride : 0.5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Mitoxantrone dihydrochloride : 0.5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Mitoxantrone dihydrochloride Heparin sodium		3640
		Mitoxantrone dihydrochloride : 0.5 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Mitoxantrone dihydrochloride : 0.5 mg/ml Linezolid : 2 mg/ml		1925
		Mitoxantrone dihydrochloride : 0.5 mg/ml Melphalan : 0.1 mg/ml		169
		Mitoxantrone dihydrochloride : 0.5 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Mitoxantrone dihydrochloride : 0,5 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Mitoxantrone dihydrochloride : 0.5 mg/ml Paclitaxel : 1.2 mg/ml		248
		Mitoxantrone dihydrochloride : 0.5 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Mitoxantrone dihydrochloride : 0.5 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Mitoxantrone dihydrochloride : 0.5 mg/ml Propofol : 10 mg/ml		300
		Mitoxantrone dihydrochloride : 0.5 mg/ml Sargramostim : 10 µg/ml		335
		Mitoxantrone dihydrochloride : 0.5 mg/ml Teniposide : 0.1 mg/ml		905
		Mitoxantrone dihydrochloride : 0.5 mg/ml Thiotepa : 1 mg/ml		249
		Mitoxantrone dihydrochloride : 0.5 mg/ml Vinorelbine tartrate : 1 mg/ml		84



**Bibliographie**

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.

334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
484	Revue	Northcott M, Allsopp MA, Powell H, Sewell GJ. The stability of carboplatin, diamorphine, 5-fluorouracil and mitoxantrone infusions in an ambulatory pump under storage and prolonged "in use" conditions. J Clin Pharm Ther 1991 ; 16: 123-129.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
828	Revue	Lecompte D, Bousselet M, Magnam J. Stability of mitoxantrone (Novantrone*) after dilution in PVC infusions. J Pharm Clin 1990 ; 9: 159-165.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1317	Revue	Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG. Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J 1987 ; 238: 476-478.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1730	Revue	Björkman S, Roth B. Chemical compatibility of mitoxantrone and etoposide (VP-16). Act Pharm Nord 1991 ; 3: 251.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.

1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2344	Laboratoire	Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution. Ebewe Pharma 2009
3640	Laboratoire	Mitoxantrone - Summary of Product Characteristics Hospira 2013



# Dictionnaire

 Anticancéreux	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Chlorure de sodium 0,9%	 A l'abri de la lumière
 Jour	 Lumière
 Glucose 5%	 Polyvinyl chlorure
 Eau pour préparation injectable	 NaCl 0,9% ou glucose 5%
 Non précisée	 Polyéthylène
 Seringue polypropylène	 Stabilité en mélange
 Solvant	 Molécule
 Non précisé	 Aucun
 Heure	 Facteur influençant la stabilité
 Nutrition parentérale (mélange binaire)	 Provoque
 Dégradation	 Compatibilités
 Précipitation immédiate	 Incompatible
 Précipitation en 1 heure	 Perte de turbidité
 Compatible	 Nutrition parentérale (mélange ternaire)
 NaCl 0,9% + bactériostatique	 Incompatibilité non précisée
 Voie d'administration	 Perfusion intraveineuse
 Bibliographie	 Dictionnaire